{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:50:24Z","timestamp":1753890624821,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:p>Injury from medication use, known as an adverse drug event (ADE) accounts for millions of emergency department visits globally and thousands of hospitalizations annually within the United States. Efforts to prevent and detect ADEs within healthcare systems are complicated by data quality, lack of data standardization, and actionable clinical decision support systems. United States Pharmacopeia (USP) proposes the use of an ADE value set, a standardized grouping of medical terms, to improve the identification, documentation, and use of ADE information in EHRs. Artificial Intelligence and Machine Learning capabilities would be further strengthened through the standardization of ADE data and information.<\/jats:p>","DOI":"10.3389\/fdgth.2025.1507967","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:27:56Z","timestamp":1743157676000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A call to action for adverse drug event (ADE) detection and prevention"],"prefix":"10.3389","volume":"7","author":[{"given":"John","family":"McCue","sequence":"first","affiliation":[]},{"given":"C. David","family":"Butler","sequence":"additional","affiliation":[]},{"given":"Raymond C.","family":"Love","sequence":"additional","affiliation":[]},{"given":"Shelly","family":"Spiro","sequence":"additional","affiliation":[]},{"given":"Roy","family":"Guharoy","sequence":"additional","affiliation":[]},{"name":"the United States Pharmacopeia (USP) Allergy & Intolerance Classification Expert Panel","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"year":"2024","key":"B1","article-title":"FastStats: Medication Safety Data. Medication Safety Program"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jama.2021.13844","article-title":"US emergency department visits attributed to medication Harms, 2017\u20132019","volume":"326","author":"Budnitz","year":"2021","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"eaau6753","DOI":"10.1126\/scitranslmed.aau6753","article-title":"\u201cInactive\u201d ingredients in oral medications","volume":"11","author":"Reker","year":"2019","journal-title":"Sci Transl Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jbi.2012.06.005","article-title":"Cross-terminology mapping challenges: a demonstration using medication terminological systems","volume":"45","author":"Saitwal","year":"2012","journal-title":"J Biomed Inform"},{"key":"B5","first-page":"195","article-title":"Clinical decision support alert appropriateness: a review and proposal for improvement","volume":"14","author":"McCoy","year":"2014","journal-title":"Ochsner J"},{"year":"2019","key":"B6","article-title":"ICD-10 Version:2019. icd.who.int"},{"year":"2024","key":"B7","article-title":"Healthit.gov"},{"year":"","key":"B8","article-title":"Value set | eCQI Resource Center. ecqi.healthit.gov"},{"key":"B9","first-page":"480","article-title":"Clinical concept value sets and interoperability in health data analytics","volume":"2018","author":"Gold","year":"2018","journal-title":"AMIA Annu Symp Proc"},{"year":"2018","key":"B10","article-title":"HL7 Cross Paradigm Specification: Allergy and Intolerance Substance Value Set(s) Definition Release 1 HL7 Informative Ballot"},{"year":"","key":"B11","article-title":"Understanding C-CDA and the C-CDA Companion Guide - Consolidated CDA Release 2.1. build.fhir.org"},{"key":"B12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/11596570-000000000-00000","article-title":"Methods for assessing the preventability of adverse drug events","volume":"35","author":"Hakkarainen","year":"2012","journal-title":"Drug Saf"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2025.1507967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:28:12Z","timestamp":1743157692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2025.1507967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":12,"alternative-id":["10.3389\/fdgth.2025.1507967"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2025.1507967","relation":{},"ISSN":["2673-253X"],"issn-type":[{"type":"electronic","value":"2673-253X"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"1507967"}}